- Home
- OMER vs DENN Comparison
OMER vs DENN Comparison
Compare OMER & DENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- DENN
- Stock Information
- Founded
- OMER 1994
- DENN 1953
- Country
- OMER United States
- DENN United States
- Employees
- OMER N/A
- DENN N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- DENN Restaurants
- Sector
- OMER Health Care
- DENN Consumer Discretionary
- Exchange
- OMER Nasdaq
- DENN Nasdaq
- Market Cap
- OMER 274.3M
- DENN 265.2M
- IPO Year
- OMER 2009
- DENN 1989
- Fundamental
- Price
- OMER $4.48
- DENN $5.03
- Analyst Decision
- OMER Strong Buy
- DENN Strong Buy
- Analyst Count
- OMER 5
- DENN 7
- Target Price
- OMER $18.00
- DENN $6.96
- AVG Volume (30 Days)
- OMER 933.6K
- DENN 878.1K
- Earning Date
- OMER 11-12-2025
- DENN 10-31-2025
- Dividend Yield
- OMER N/A
- DENN N/A
- EPS Growth
- OMER N/A
- DENN N/A
- EPS
- OMER N/A
- DENN 0.30
- Revenue
- OMER N/A
- DENN $455,727,000.00
- Revenue This Year
- OMER N/A
- DENN $7.57
- Revenue Next Year
- OMER N/A
- DENN $1.89
- P/E Ratio
- OMER N/A
- DENN $16.69
- Revenue Growth
- OMER N/A
- DENN 0.06
- 52 Week Low
- OMER $2.95
- DENN $2.85
- 52 Week High
- OMER $13.60
- DENN $7.73
- Technical
- Relative Strength Index (RSI)
- OMER 56.41
- DENN 51.60
- Support Level
- OMER $4.07
- DENN $5.05
- Resistance Level
- OMER $4.72
- DENN $5.31
- Average True Range (ATR)
- OMER 0.23
- DENN 0.27
- MACD
- OMER 0.02
- DENN -0.07
- Stochastic Oscillator
- OMER 61.19
- DENN 25.33
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About DENN Denny's Corporation
Denny's Corp is America's franchised full-service restaurant chains based on the number of restaurants. The company owns and operates the Denny's brand and the Keke's Breakfast Cafe brand. It provides Pancakes, Appetizers & Soups, Sandwiches & Salads, Breakfast Melts, Omelets, and others. The company generates its revenue from two sources: the sale of food and beverages and the collection of royalties, advertising revenue, initial and other fees, including occupancy revenue, from restaurants operated by their franchisees. Geographically operates in USA states as well as globally like Canada, Mexico, Guatemala, Indonesia, United Kingdom, New Zealand and others. Maximum revenue is from USA and Canada.